Deutsche Biotech Innovativ AG Logo

Deutsche Biotech Innovativ AG

Develops therapeutics for serious diseases using innovative blood biomarkers.

DBI | F

Overview

Corporate Details

ISIN(s):
DE000A0Z25L1
LEI:
391200BIDNL2ZOKI1M61
Country:
Germany
Address:
Neuendorfstraße 15a, 16761 Hennigsdorf

Description

Deutsche Biotech Innovativ AG is a biotechnology company focused on the research and clinical development of therapeutic solutions for serious diseases. The company utilizes innovative blood biomarkers to guide its development process. Its lead product candidate is Adrecizumab, a monoclonal, adrenomedullin-specific antibody designed to treat conditions involving endothelial barrier dysfunction. Adrecizumab has completed Phase I/II clinical trials for the treatment of septic shock.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2011-08-24 10:51
Venetus Beteiligungen AG: Hauptversammlung beschliet alle Tagesordnungspunkte i…
German 2.4 KB
2011-02-21 16:27
Venetus Beteiligungen AG: Neuer Aufsichtsrat bestellt
German 4.0 KB
2011-01-13 15:11
Venetus Beteiligungen AG: Kapitalerhohung erfolgreich platziert
German 2.6 KB
2010-12-10 08:45
Venetus Beteiligungen AG: Gesellschafter- und Vorstandswechsel,Kauf von 40 % an…
German 4.0 KB
2010-05-31 13:00
Venetus Beteiligungen AG: Notierungsaufnahme
German 1.7 KB

Automate Your Workflow. Get a real-time feed of all Deutsche Biotech Innovativ AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Deutsche Biotech Innovativ AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Deutsche Biotech Innovativ AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.